|
Nkarta, Inc. (NKTX) DCF Valuation
US | Healthcare | Biotechnology | NASDAQ
|
- ✓ Fully Editable: Tailor To Your Needs In Excel Or Sheets
- ✓ Professional Design: Trusted, Industry-Standard Templates
- ✓ Pre-Built For Quick And Efficient Use
- ✓ No Expertise Is Needed; Easy To Follow
Nkarta, Inc. (NKTX) Bundle
Discover Nkarta, Inc.'s (NKTX) true potential with our advanced DCF Calculator! Adjust key assumptions, explore various scenarios, and evaluate how modifications affect Nkarta, Inc.'s (NKTX) valuation – all within a comprehensive Excel template.
Discounted Cash Flow (DCF) - (USD MM)
Year | AY1 2019 |
AY2 2020 |
AY3 2021 |
AY4 2022 |
AY5 2023 |
FY1 2024 |
FY2 2025 |
FY3 2026 |
FY4 2027 |
FY5 2028 |
---|---|---|---|---|---|---|---|---|---|---|
Revenue | .1 | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 |
Revenue Growth, % | 0 | -100 | 0 | 0 | 0 | -25 | -25 | -25 | -25 | -25 |
EBITDA | -20.0 | -90.3 | -84.0 | -107.3 | -120.5 | .0 | .0 | .0 | .0 | .0 |
EBITDA, % | -17376.38 | 100 | 100 | 100 | 100 | 60 | 60 | 60 | 60 | 60 |
Depreciation | .6 | 1.0 | 2.1 | 6.6 | 5.9 | .0 | .0 | .0 | .0 | .0 |
Depreciation, % | 479.51 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 |
EBIT | -20.6 | -91.4 | -86.1 | -113.8 | -126.4 | .0 | .0 | .0 | .0 | .0 |
EBIT, % | -17855.89 | 100 | 100 | 100 | 100 | 60 | 60 | 60 | 60 | 60 |
Total Cash | 37.0 | 315.3 | 240.2 | 354.9 | 248.2 | .0 | .0 | .0 | .0 | .0 |
Total Cash, percent | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 |
Account Receivables | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 |
Account Receivables, % | 0 | 100 | 100 | 100 | 100 | 80 | 80 | 80 | 80 | 80 |
Inventories | .0 | .0 | .0 | -4.2 | .0 | .0 | .0 | .0 | .0 | .0 |
Inventories, % | 0 | 100 | 100 | 100 | 100 | 80 | 80 | 80 | 80 | 80 |
Accounts Payable | 1.9 | 1.2 | 1.1 | 1.8 | 3.7 | .0 | .0 | .0 | .0 | .0 |
Accounts Payable, % | 1631.06 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 |
Capital Expenditure | -1.9 | -7.5 | -5.0 | -47.1 | -28.1 | .0 | .0 | .0 | .0 | .0 |
Capital Expenditure, % | -1671.19 | 100 | 100 | 100 | 100 | -20 | -20 | -20 | -20 | -20 |
Tax Rate, % | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
EBITAT | -22.4 | -50.4 | -83.9 | -119.4 | -126.4 | .0 | .0 | .0 | .0 | .0 |
Depreciation | ||||||||||
Changes in Account Receivables | ||||||||||
Changes in Inventories | ||||||||||
Changes in Accounts Payable | ||||||||||
Capital Expenditure | ||||||||||
UFCF | -21.9 | -57.6 | -86.9 | -155.1 | -151.0 | -3.7 | .0 | .0 | .0 | .0 |
WACC, % | 6.8 | 5.95 | 6.76 | 6.8 | 6.8 | 6.62 | 6.62 | 6.62 | 6.62 | 6.62 |
PV UFCF | ||||||||||
SUM PV UFCF | -3.4 | |||||||||
Long Term Growth Rate, % | 2.00 | |||||||||
Free cash flow (T + 1) | 0 | |||||||||
Terminal Value | 0 | |||||||||
Present Terminal Value | 0 | |||||||||
Enterprise Value | -3 | |||||||||
Net Debt | 57 | |||||||||
Equity Value | -61 | |||||||||
Diluted Shares Outstanding, MM | 49 | |||||||||
Equity Value Per Share | -1.24 |
What You Will Receive
- Customizable Excel Template: A fully adjustable Excel-based DCF Calculator featuring pre-filled real NKTX financials.
- Actual Data: Historical figures and forward-looking projections (displayed in the highlighted cells).
- Flexible Forecasting: Modify forecast parameters such as revenue growth, EBITDA %, and WACC.
- Instant Calculations: Quickly observe how your inputs affect Nkarta's valuation.
- Professional Resource: Designed for investors, CFOs, consultants, and financial analysts.
- Intuitive Layout: Organized for clarity and simplicity, complete with step-by-step guidance.
Key Features
- Customizable Financial Inputs: Adjust essential factors such as revenue projections, R&D investment, and operating expenses.
- Instant DCF Valuation: Quickly computes intrinsic value, NPV, and additional financial metrics.
- Precision-Driven Results: Leverages Nkarta’s actual financial data for credible valuation results.
- Streamlined Scenario Analysis: Effortlessly evaluate various assumptions and analyze different outcomes.
- Efficiency Booster: Avoid the hassle of constructing intricate valuation models from the ground up.
How It Works
- Step 1: Download the Excel file.
- Step 2: Review Nkarta, Inc.'s pre-filled financial data and forecasts.
- Step 3: Modify key inputs such as revenue growth, WACC, and tax rates (highlighted cells).
- Step 4: Observe the DCF model update in real-time as you adjust the assumptions.
- Step 5: Evaluate the outputs and leverage the results for investment decisions related to Nkarta, Inc. (NKTX).
Why Choose This Calculator for Nkarta, Inc. (NKTX)?
- Designed for Experts: A sophisticated tool tailored for analysts, CFOs, and industry consultants.
- Accurate Data: Nkarta’s historical and projected financials are preloaded for precise calculations.
- Scenario Analysis: Effortlessly simulate various forecasts and assumptions.
- Comprehensive Outputs: Automatically computes intrinsic value, NPV, and essential metrics.
- User-Friendly: Step-by-step guidance ensures a smooth experience throughout the process.
Who Should Use This Product?
- Individual Investors: Make informed decisions about buying or selling Nkarta, Inc. (NKTX) stock.
- Financial Analysts: Streamline valuation processes with ready-to-use financial models for Nkarta, Inc. (NKTX).
- Consultants: Deliver professional valuation insights on Nkarta, Inc. (NKTX) to clients quickly and accurately.
- Business Owners: Understand how companies like Nkarta, Inc. (NKTX) are valued to guide your own strategy.
- Finance Students: Learn valuation techniques using real-world data and scenarios related to Nkarta, Inc. (NKTX).
What the Template Contains
- Pre-Filled DCF Model: Nkarta, Inc.’s (NKTX) financial data preloaded for immediate use.
- WACC Calculator: Detailed calculations for Weighted Average Cost of Capital.
- Financial Ratios: Evaluate Nkarta, Inc.’s (NKTX) profitability, leverage, and efficiency.
- Editable Inputs: Change assumptions such as growth, margins, and CAPEX to fit your scenarios.
- Financial Statements: Annual and quarterly reports to support detailed analysis.
- Interactive Dashboard: Easily visualize key valuation metrics and results.